Literature DB >> 2788388

Lack of dynamic lipid changes after binding of interleukin 2 in chronic lymphatic leukemia lymphocytes indicates defective transmembrane signalling.

S Daefler1, G R Krueger.   

Abstract

The role of membrane fluidity in the process of signal transduction after binding of Interleukin-2 (Il-2) to its specific cell-surface receptor was investigated in lymphocytes from normal donors and patients with Chronic Lymphocytic Leukemia (CLL). Membrane fluidity was assessed by fluorescence polarization analysis of the apolar fluorophor 1,6-diphenyl-1, 3, 5-hexatrien (DPH) incorporated in the lipid core of the cell membrane. Phytohemagglutinin (PHA) stimulation of lymphocytes for 72h disclosed marked membrane fluidization in normal lymphocytes without affecting lipid phase separation lacking in leukemic cells. Binding of Il-2 induced a significant decrease of the thermotropic transition temperature and overall membrane fluidization within 1h. These effects were not observed in CLL lymphocytes. Results are discussed in terms of defective transmembrane signalling in leukemic cells and pathogenetic implications for uncoupling from proliferation and differentiation signals in the development of leukemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788388

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Effects of Ibrutinib on biophysical parameters of platelet in patients with chronic lymphocytic leukaemia.

Authors:  Viola Maria Popov; Christien Oktaviani Matei; Meilin Omer; Minodora Onisai; Mircea Bogdan Matei; Tudor Savopol; Horia Bumbea; Mihaela G Moisescu
Journal:  Am J Blood Res       Date:  2020-12-15

2.  A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

Authors:  Mariam Hammadi; Jacques-Olivier Pers; Christian Berthou; Pierre Youinou; Anne Bordron
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.